Ra Pharmaceuticals (NASDAQ:RARX) Upgraded at ValuEngine

ValuEngine upgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday morning, ValuEngine reports.

Other equities research analysts have also issued reports about the stock. BidaskClub lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, March 29th. Zacks Investment Research raised shares of Ra Pharmaceuticals from a hold rating to a buy rating and set a $24.00 price target on the stock in a research note on Tuesday, June 11th. SunTrust Banks raised their price target on shares of Ra Pharmaceuticals to $42.00 and gave the company a buy rating in a research note on Friday, May 17th. Jefferies Financial Group raised their price target on shares of Ra Pharmaceuticals from $40.00 to $45.00 and gave the company a buy rating in a research note on Tuesday, June 18th. Finally, Svb Leerink initiated coverage on shares of Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They issued an outperform rating and a $33.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Ra Pharmaceuticals has an average rating of Buy and an average target price of $37.73.

RARX stock opened at $32.47 on Tuesday. The stock’s 50-day moving average price is $24.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.10 and a current ratio of 20.10. Ra Pharmaceuticals has a 52-week low of $8.67 and a 52-week high of $34.50.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02. Sell-side analysts forecast that Ra Pharmaceuticals will post -1.98 earnings per share for the current fiscal year.

In other Ra Pharmaceuticals news, insider Simon Read sold 10,000 shares of the stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $22.25, for a total value of $222,500.00. Following the completion of the sale, the insider now owns 8,521 shares in the company, valued at approximately $189,592.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alonso Ricardo sold 2,857 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $23.72, for a total transaction of $67,768.04. Following the completion of the sale, the insider now owns 11,428 shares of the company’s stock, valued at approximately $271,072.16. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. RA Capital Management LLC raised its holdings in Ra Pharmaceuticals by 26.1% in the 4th quarter. RA Capital Management LLC now owns 4,858,260 shares of the company’s stock valued at $33,963,000 after acquiring an additional 1,006,452 shares during the last quarter. BlackRock Inc. raised its holdings in Ra Pharmaceuticals by 29.0% in the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock valued at $48,142,000 after acquiring an additional 595,328 shares during the last quarter. Candriam Luxembourg S.C.A. raised its holdings in Ra Pharmaceuticals by 16.5% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 1,024,000 shares of the company’s stock valued at $22,939,000 after acquiring an additional 145,000 shares during the last quarter. Sectoral Asset Management Inc raised its holdings in Ra Pharmaceuticals by 129.3% in the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock valued at $14,553,000 after acquiring an additional 450,900 shares during the last quarter. Finally, FMR LLC raised its holdings in Ra Pharmaceuticals by 12.9% in the 1st quarter. FMR LLC now owns 466,834 shares of the company’s stock valued at $10,457,000 after acquiring an additional 53,445 shares during the last quarter. Institutional investors own 94.97% of the company’s stock.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: How to calculate compound interest

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.